HIM
STML

Hillsdale Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Hillsdale Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-9,600
Closed -$61K – 571
2015
Q4 		$61K Buy
+9,600
New +$77.9K 0.02% 325

Other funds holding STML

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hillsdale Investment Management's STML Position: Q1 2016 in Review

Hillsdale Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2016, closing a stake of 9,600 shares — an estimated $61K sold.

Hillsdale Investment Management first reported a position in STML in Q4 2015 and held it in 1 quarter. The position peaked at $61K in Q4 2015. 63 funds tracked by Wall St. Rank hold STML as of Q1 2016.

  • Hillsdale Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Hillsdale Investment Management sold 9,600 Stemline Therapeutics, Inc. shares in Q1 2016, an estimated $61K.
  • Hillsdale Investment Management first reported a position in Stemline Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Hillsdale Investment Management's Stemline Therapeutics, Inc. position peaked at $61K in Q4 2015.
  • 63 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2016.

Based on Hillsdale Investment Management's 13F filing for Q1 2016, filed 10 May 2016.